Format

Send to

Choose Destination
Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15946. [Epub ahead of print]

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Author information

1
Complejo Asistencial Universitario de Salamanca/IBSAL & Centro de Investigación del Cáncer (IBMCC-CSIC-USAL), Salamanca, Spain.
2
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3
Hospital Universitario Marqués de Valdecilla (IDIVAL) & University of Cantabria, Santander, Spain.
4
Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
5
Princess Margaret Cancer Centre, Toronto, ON, Canada.
6
University Hospital Hotel-Dieu, Nantes, France.
7
Dana-Farber Cancer Institute, Boston, MA, USA.
8
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
9
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
10
Merck & Co, Inc, Kenilworth, NJ, USA.

KEYWORDS:

dexamethasone; lenalidomide; multiple myeloma; pembrolizumab; relapsed/refractory

PMID:
31090915
DOI:
10.1111/bjh.15946

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center